Overview

Randomized Amifostine For SCCHN

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This research study is studying a drug called Amifostine as a treatment for squamous cell carcinoma in the head and/or neck area.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
AstraZeneca
MedImmune LLC
National Cancer Institute (NCI)
Treatments:
Albumin-Bound Paclitaxel
Amifostine
Carboplatin
Paclitaxel